SVA Sernova Biotherapeutics Inc

0.0629USD0.0900 CAD · TSX-10.00%Mkt Cap: 23.76M USDP/E: 9.00

Sernova Biotherapeutics Inc operates as a clinical-stage biotechnology company in Canada. The company develops regenerative medicine therapeutics comprising proprietary Cell Pouch, a bio-hybrid organ system to replicate …

Institutional holders1 on file

Key Statistics

Company
Market Cap23.76M USD
Enterprise Value33.93M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-11.01M USD
Revenue/Share—
Last Price0.0629 USD
Fiscal Year EndOct 2025
MR QuarterJul 2026
Employees8
CountryCA
SectorHealthcare
IndustryBiotechnology
ISINCA81752F1062
Valuation
P/E (Trailing)9.00
P/E (Forward)-3.00
PEG—
EV/EBITDA-5.43
EV/Revenue—
P/S—
P/B-1.43
EPS (TTM)0.0070 USD
EPS (Forward)-0.02 USD
52W Range
0.06290% of range0.1398
52W High0.1398 USD
52W Low0.0629 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE62.78%
ROA-2060.03%
ROIC—
ROCE—
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-7.63M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-43.64%
Net Debt1.76M USD
Net Debt/EBITDA-0.28
Net Debt/FCF—
Balance Sheet
Debt/Equity-0.19
Current Ratio0.03
Quick Ratio0.01
Book Value/Sh-0.04 USD
Cash/Share0.00 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)0.6990 USD
Upside (mean)+1011.1%
Target Range0.6990 USD – 0.6990 USD
# Analysts1
Ownership
Shares Out.377.64M
Float336.77M
Insiders10.51%
Institutions0.04%
Short Interest
Short Ratio1.0d
Short % Out.0.02%
Shares Short84.36K
Short (prev mo.)747.30K
Technical
SMA 500.0776 (-18.9%)
SMA 2000.0958 (-34.3%)
Beta0.67
S&P 52W Chg12.00%
Avg Vol (30d)76.29K
Avg Vol (10d)99.22K
Technical Indicators
RSI (14)34.2
MACD-0.0031
MACD Signal-0.0015
MACD Hist.-0.0016
BB Upper0.0823 USD
BB Middle0.0744 USD
BB Lower0.0666 USD
BB Width21.19%
ATR (14)0.0062 USD
Vol Ratio (20d)1.27x

About Sernova Biotherapeutics (TSE: SVA)

›

Sernova Biotherapeutics (TSE: SVA) is listed on the Toronto Stock Exchange, where its shares trade in CAD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 8 employees.

The shares were at 0.0900 CAD on 19 November 2026, down 35.7% over 52 weeks. Its 52-week range is 0.0900 CAD to 0.2000 CAD, and it trades at the bottom of that range.

At a market capitalisation of 33.99M CAD, it trades at 9.0 times trailing earnings. The median trailing P/E of its 13 largest Biotechnology peers is 33.5, a discount of 73% for SVA.

Sernova Biotherapeutics reports return on equity of 62.8% and an operating margin of 0.0%.

Its debt exceeds its cash by 2.52M CAD. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health. The next earnings report is expected on 17 December 2026.